Cost-Effectiveness of HPV Vaccination in the United States
Author Information
Author(s): Chesson Harrell W., Ekwueme Donatus U., Saraiya Mona, Markowitz Lauri E.
Primary Institution: Centers for Disease Control and Prevention
Hypothesis
What is the cost per QALY gained by adding vaccination of 12-year-old girls to existing cervical cancer screening practices in the United States?
Conclusion
The cost per QALY gained by adding routine vaccination of 12-year-old girls to existing screening practices ranged from $3,906 to $14,723 under base-case parameter values.
Supporting Evidence
- The estimated cost per QALY gained by vaccination ranged from $3,906 to $14,723 depending on various factors.
- The results were consistent with published studies based on more complex models.
- The model required fewer assumptions than more complex models, making it simpler to use.
- Vaccination is expected to reduce the number of abnormal Pap results overall.
Takeaway
This study looks at how much it costs to save a year of healthy life by vaccinating girls against HPV, and it finds that the vaccination is a good deal for health.
Methodology
A simplified model was developed to estimate the cost-effectiveness of HPV vaccination based on current economic and health effects.
Limitations
The model does not directly account for cervical cancer screening strategies and may underestimate the benefits of vaccination.
Participant Demographics
Hypothetical population of persons aged 12–99 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website